Fintel reports that on August 4, 2025, Wolfe Research downgraded their outlook for Vera Therapeutics (NasdaqGM:VERA) from Outperform to Peer Perform.

Analyst Price Forecast Suggests 214.60% Upside

As of July 17, 2025, the average one-year price target for Vera Therapeutics is $65.91/share. The forecasts range from a low of $23.23 to a high of $105.00. The average price target represents an increase of 214.60% from its latest reported closing price of $20.95 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Vera Therapeutics is 29MM. The projected annual non-GAAP EPS is -3.30.

What is the Fund Sentiment?

There are 382 funds or institutions reporting positions in Vera Therapeutics. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to VERA is 0.17%, an increase of 42.07%. Total shares owned by institutions decreased in the last three months by 1.34% to 67,197K shares. The put/call ratio of VERA is 1.04, indicating a bearish outlook.

What are Other Shareholders Doing?

Avoro Capital Advisors holds 5,702K shares representing 8.94% ownership of the company. In its prior filing, the firm reported owning 5,610K shares , representing an increase of 1.61%. The firm decreased its portfolio allocation in VERA by 36.29% over the last quarter.

Price T Rowe Associates holds 4,755K shares representing 7.46% ownership of the company. In its prior filing, the firm reported owning 4,377K shares , representing an increase of 7.95%. The firm decreased its portfolio allocation in VERA by 34.05% over the last quarter.

Sofinnova Investments holds 2,794K shares representing 4.38% ownership of the company. No change in the last quarter.

Commodore Capital holds 2,562K shares representing 4.02% ownership of the company. In its prior filing, the firm reported owning 1,959K shares , representing an increase of 23.55%. The firm decreased its portfolio allocation in VERA by 25.30% over the last quarter.

Vestal Point Capital holds 2,500K shares representing 3.92% ownership of the company. In its prior filing, the firm reported owning 1,075K shares , representing an increase of 57.00%. The firm increased its portfolio allocation in VERA by 59.10% over the last quarter.